MedTrace Logo

Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma

NCT06553352 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2024-09-03

No results posted yet for this study

Summary

To evaluate the efficacy and side effects of Zanubrutinib combined with Obinutuzumab (ZO) in the treatment of newly diagnosed follicular lymphoma.

Conditions

Interventions

DRUG

Zanubrutinib combined with Obinutuzumab

Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days.

Sponsors & Collaborators

  • Shaanxi Provincial Cancer Hospital

    collaborator OTHER

  • The First Hospital of Jilin University

    collaborator OTHER

  • Fujian Cancer Hospital

    collaborator OTHER_GOV

  • Jiangxi Provincial Cancer Hospital

    collaborator OTHER

  • The Second Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Huazhong University of Science and Technology

    collaborator OTHER

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Principal Investigators

  • Bing Xu · The First Aiffiliated hosptical of xiamen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-31
Primary Completion
2026-04-20
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06553352 on ClinicalTrials.gov